Panbela Therapeutics
Manufacturing · Minnesota, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
712 Vista Blvd Pmb 305, Waconia, Minneso...Phone Number
(952) 479-1196Website
www.panbela.comRevenue
<$5 MillionStock Symbol
PBLAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Panbela Therapeutics
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents in other cancer indications.Explore more
Panbela Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Panbela Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Panbela Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Panbela Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Panbela Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Panbela Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Panbela Therapeutics
Product Launch: Get notified when Panbela Therapeutics launches new products
Earning: See what the market has to say on Panbela Therapeutics recently announced quarterly report
Check out if Panbela Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Panbela Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Panbela Therapeutics
Compare insights from companies similar to Panbela Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Panbela Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Panbela Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Panbela Therapeutics.
Panbela Therapeutics Tech Stack
A closer look at the technologies used by Panbela Therapeutics
Most Recent Scoops
Earnings
reported general and administrative expenses of approximately $1.1 million in Q3 of 2024, flat compared to the same quarter last year. Research and development expenses were approximately $6.1 million, down from $6.7 million in the prior year quarter. Net loss for the quarter was $7.2 million, or $1.48 per diluted share.
Earnings, Accounting, Financial Reporting, Finance
Project
Panbela Therapeutics has announced clinical milestones for 2024-2025, including opening a neoadjuvant pancreatic cancer trial and a phase 2 ovarian trial in early 2025, submitting the FAP global registration protocol to the FDA and EMA, and conducting the overall survival interim analysis for the Phase III ASPIRE trial in Q1 2025.
Search, Medical Research, Clinical Operations, Operations
Project
Panbela Therapeutics is exploring the potential of polyamine modulation to reinvigorate immune response in STIK11 mutant non-small cell lung cancer patients, a population that historically responds poorly to checkpoint inhibitors. The company plans to advance to Phase 2 to evaluate efficacy once safety is established in Phase 1.
Search, Medical Research, Clinical Operations, Operations
Project
Panbela Therapeutics is conducting the Phase 3 ASPIRE Global Clinical Trial, evaluating ibuprofen (SVP 101) in combination with gemcitabine and nabpaclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma. The safety database has expanded throughout 2024, with a consistent safety profile observed through Data Safety Monitoring Board meetings.
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Earnings
Earnings, Accounting, Financial Reporting, Finance
Panbela Therapeutics News & Media
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024.First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combinatPanbela Provides Business Update and Reports Q2 2024 Financial Results
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Panbela Therapeutics
Sign Up For FreeTo access detailed company insights
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics... Read More
